<DOC>
	<DOCNO>NCT03032315</DOCNO>
	<brief_summary>randomize , open-label , single dose , replicate crossover clinical trial compare pharmacokinetics TAH ( 80/10/12.5 ) tablet comparison co-administration telmisartan , amlodipine hydrochlorothiazide healthy male volunteer</brief_summary>
	<brief_title>Compare Pharmacokinetics TAH ( 80/10/12.5 ) Tablet Comparison Co-administration Telmisartan , Amlodipine Hydrochlorothiazide Healthy Male Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Telmisartan</mesh_term>
	<mesh_term>Hydrochlorothiazide</mesh_term>
	<mesh_term>Amlodipine</mesh_term>
	<criteria>1 . Healthy male volunteer age 19 55 year 2. body mass index ( BMI ) 17.530.5kg/m2 weigh 55kg 3 . Subject congenital chronic disease without pathologic symptom find medical exam . 4 . Subject determine eligible accord result clinical laboratory test like serum test , hematologic test , blood chemistry test , urine test etc . vital sign , electrocardiography , physical exam etc . perform screen exam . 5 ) willing able provide write informed consent 1 . Evidence history clinically significant hematological , renal , endocrine , pulmonary , gastrointestinal , cardiovascular , hepatic , psychiatric , neurologic , allergic disease ( include drug allergy , exclude untreated , asymptomatic , seasonal allergy time dose ) 2 . A subject history gastrointestinal disease surgery ( except simple appendectomy repair hernia ) , influence absorption study drug 3 . History regular alcohol consumption ( &gt; 210 g/week ) within 6 month screen visit . 4 . Subjects take medication involve clinical trial bioequivalence test within three month first dose medication character . 5 . Seated systolic blood pressure &lt; 100mmHg ≥ 150 mmHg , diastolic blood pressure &lt; 600mmHg ≥ 100mmHg screen visit 6 . History alcohol drug abuse within 12 month screen visit 7 . Subjects treat metabolize enzyme inducer inhibitor barbital within 30days prior first dosing . 8 . Smoker smoke 20 cigarette per day 9 . Subjects take ethical count count medicine within 10days first investigational product administration . 10 . Blood Subjects whole blood donation within two month component blood donation within 1month prior first dosing . 11 . Subjects increase risk due clinical test administration drug Severe grade / chronic medical , mental condition abnormal laboratory result may interfere analysis test result . 12 . Subject know hypersensitivity reaction TWYNSTA TAB dihydropyridine derivatives 13 . Subject know hypersensitivity reaction thiazide diuretic Sulfonamides 14 . Patients biliary obstructive disorder 15 . Patients receive drug affect RAAS Angiotensin Receptor Blocker ( ARB ) , ACE inhibitor aliskiren 16 . Combination aliskiren Diabetic patient moderate severe renal insufficient subject ( glomerular filtration rate &lt; 60mL/min/1.73m2 ) 17 . Patients severe hepatic impairment 18 . Patients severe aortic stenosis 19 . Patients history shock 20 . Patients anuria 21 . Patients acute severe renal failure 22 . Patients hyponatraemia hypokalemia 23 . Patients Addison 's disease 24 . Patients hypercalcemia malignancy 25. Who Galactose intolerance , LAPP lactose intolerance , glucosegalactose malabsorption genetic disorder 26 . Test subject willing unable comply guideline describe protocol 27 . A person determine unsuitable participate test researcher</criteria>
	<gender>Male</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>